Abivax sa - adr ABVX.US Overview Analysis
ABVX AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
ABVX Current Performance
-1.85%
Abivax sa - adr
0.23%
Avg of Sector
0.43%
S&P500
Top 10 High Relevance to ABVX
- BCAX Bicara therapeutics incValue -Trend 3Swing Trading 4Whale Interest 3Dividend 1See more
ABVX Profile
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.